28 results
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, subcontracts, agreement, instrument, lease, license, commitment, sales and purchase orders, and other instruments, arrangements or understandings of any kind … , liability, claim, expense, Tax, commitment or obligation of whatever kind, whether known or unknown, direct or indirect, accrued or fixed, absolute
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
as breakthrough therapies are eligible for intensive guidance from the FDA on an efficient development program, organizational commitment to the development
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
are eligible for intensive guidance from the FDA on an efficient development program, organizational commitment to the development and review of the product
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
are eligible for intensive guidance from the FDA on an efficient development program, organizational commitment to the development and review
DEFA14A
ELYM
Eliem Therapeutics Inc
11 Apr 24
Additional proxy soliciting materials
8:10am
, representing an aggregate commitment of at least $120 million, in substantially the form attached hereto as Exhibit A (collectively, the “Securities … such option, warrant, Equity Interest, call, right, commitment or agreement, (iii) the Company has no obligation (contingent or otherwise) to issue any
8-K
EX-2.1
a1srm1do
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.3
75sbcqj5
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.3
n2dxkv wlfhgrtn3g
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
xs0u1
11 May 23
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
4:12pm
8-K
EX-99.1
s8dmn
14 Nov 22
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
6:10am
8-K
75sspkiq4p69g1o7
5 Oct 22
Eliem Therapeutics Provides Update on Pipeline Progress
7:47am
8-K
EX-99.1
t5geh10xy6jsobmi
5 Oct 22
Eliem Therapeutics Provides Update on Pipeline Progress
7:47am
8-K
EX-99.1
qrg15nulnx
15 Aug 22
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
6:15am
8-K
EX-99.1
zeqxc55k30adn2
16 May 22
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
6:24am
8-K
EX-99.1
wh69qdc0bex2ukw25 1n
7 Mar 22
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights
4:11pm
10-K
0u6s6
7 Mar 22
Annual report
4:03pm
8-K
rwh 7ioljkbb
18 Jan 22
Results of Operations and Financial Condition
5:16pm
8-K
EX-99.1
kwozn6 yzg9xb
8 Nov 21
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
4:06pm
8-K/A
EX-99.1
ee5e 3e9b1gaircve8wi
14 Sep 21
Eliem Therapeutics Reports Second Quarter Financial Results
8:01am